Products for Research Use Only

Luxdegalutamide

CAT: 0804-HY-153342-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153342-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer[1][2].
CAS Number
2750830-09-0
Product Name Alternative
ARV-766
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Androgen Receptor; PROTACs
Type
Reference compound
Related Pathways
PROTAC; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/luxdegalutamide.html
Purity
98.99
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)([C@@H](C1(C)C)NC(C2=CC=C(N3CCC(CC3)CN4CCN(C5=CC(F)=C(C=C5)C(N[C@@H]6C(NC(CC6)=O)=O)=O)CC4)C=C2)=O)[C@@H]1OC7=CC(OC)=C(C=C7)C#N
Molecular Formula
C45H54FN7O6
Molecular Weight
807.95
Precautions
H302, H315, H319
References & Citations
[1]Snyder L, et al. In vitro evaluation of PROTAC® degrader ARV-766 for cytochrome P450-and transporter-mediated drug-drug interaction[J]. Drug Metabolism and Pharmacokinetics, 2024, 55: 100881.|[2]Snyder L, et al. Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer[J]. Cancer Research, 2023, 83 (7_Supplement) : ND03-ND03.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Popular Products